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The growing number of young male cancer survivors (MCSs) and 
increasing awareness of the potential mutagenic effects of radio- 
and chemotherapy have given rise to concerns about the health of 
their offspring. Previous studies of adverse pregnancy outcomes, 
congenital abnormalities, genetic disease, and childhood cancer in 
children born to men with a history of cancer have in general been 
reassuring, both in terms of pregnancy outcome and rate of con-
genital  malformations  (1–6).  However,  these  studies  have  been 
limited in statistical power and have focused solely on children 
conceived naturally.
Both cancer and its treatment are associated with sperm DNA 
damage,  although  treatment-induced  DNA  damage  has  been 
shown  to  be  transient  (7–13).  However,  sperm  with  seriously 
impaired DNA integrity that are unable to fertilize an egg natu-
rally may still be used to conceive children via assisted reproduc-
tive technologies (ARTs), such as in vitro fertilization (IVF) or 
intracytoplasmatic sperm injection (ICSI) (14). Because cancer and its 
treatments  can  impair  fertility  (15),  MCSs  are  consequently 
expected to use ARTs to a greater extent than men in the general 
population. Therefore, paternal history of cancer and the use of 
ARTs may be associated with serious health issues in offspring.
There is an increasing awareness of the importance of events 
occurring during fetal development for not only the risk of con-
genital abnormalities and pathologies occurring early in life but 
also for morbidity later in life (16). Consequently, any investiga-
tion of a possible link between paternal cancer and adverse health 
outcomes in children should consider both perinatal conditions 
and indices of fetal growth that can affect health later in life.
Estimating the effects of relatively rare exposures such as pater-
nal  cancer  and  ARTs  on  pregnancy  outcomes  requires  large 
cohorts, particularly when the outcomes of interest occur infre-
quently in the general population (eg, congenital abnormalities). 
The unique personal identification numbers used in the Danish and 
the Swedish civil registration systems enabled us to conduct a large 
population-based register-linkage study to examine the association 
between paternal history of cancer and perinatal outcomes in live 
born children conceived naturally and those conceived using ARTs.
Subjects and Methods
Study Population and Data Sources
Using the Danish Civil Registration System, the Swedish Total 
Population Register, and the Swedish Multigenerational Register, 
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we identified both parents and all children born alive in Denmark 
between 1994 and 2004 and in Sweden between 1994 and 2005. 
We obtained detailed information about maternal and birth char-
acteristics for each child from the Danish and the Swedish Medical 
Birth Registers; additional information about congenital abnor-
malities was retrieved from the Danish and the Swedish Hospital 
Discharge  Registers  and  the  Swedish  Register  of  Congenital 
Malformations,  which  included  follow-up  until  late  2007. 
Information about the mode of conception was retrieved from the 
Danish  IVF  Register  and  the  Swedish  Medical  Birth  Register. 
Finally, we identified fathers with a history of cancer by using the 
Danish and Swedish Cancer Registers (data available until the end 
of 2003 in Denmark and 2005 in Sweden). [For a detailed descrip-
tion of the national registers used (17–25), please see the Appendix 
1.] This study was reviewed and approved by the Lund University 
Ethical  Committee  (Lund,  Sweden)  and  the  Danish  Data 
Protection Agency (Copenhagen, Denmark).
Paternal History of Cancer Designation
Children were categorized according to paternal history of cancer 
(our primary exposure of interest) and mode of conception (nat-
ural, IVF, or ICSI). We considered all diagnoses reported to the 
Danish or Swedish Cancer Registers, including diagnoses report-
able in only one of the two countries, to be cancer diagnoses. A 
child was considered to have a paternal history of cancer if the 
father was first diagnosed with cancer at least 1 year before the 
child’s  birth  (to  ensure  that  the  father’s  cancer  had  developed 
before the child was conceived). We did not restrict our analysis to 
the first child born to each father, but rather included all singletons 
born during the study period. If a MCS fathered children both 
before  and  after  his  cancer  diagnosis,  those  children  fathered 
before his diagnosis were considered not to have a paternal history 
of cancer. We excluded twins and other multiples because ARTs 
conceptions more frequently result in multiple births compared 
with natural conceptions, and multiple births tend to have more 
adverse pregnancy outcomes, including congenital abnormalities, 
than singleton gestations (20,26).
For  purposes  of  subanalyses,  paternal  history  of  cancer  was 
further  divided  into  seven  groups  based  on  the  International 
Classification of Diseases (ICD), version 7, and codes were assigned 
to paternal cancer diagnoses as follows: 1) respiratory, digestive, 
and urogenital tract cancers (excluding testicular cancer) (ICD-7 
codes 141.0–163.9, 177.0–177.9, 179.0–181.9, 195.5); 2) testicular 
cancer (ICD-1 codes 178.0–178.9); 3) skin cancers (ICD-7 codes 
140.0–140.9, 190.0–191.9); 4) eye and central nervous system can-
cers (ICD-7 codes 192.0–193.1); 5) bone and soft tissue cancers 
(ICD-7 codes 193.3, 193.8, 193.9, 196.0–197.9); 6) hematological 
malignancies (ICD-7 codes 200.0–209.9); and 7) all other cancer 
diagnoses (ICD-7 codes 164.0–164.9, 170.1, 170.2, 194.0–194.9, 
195.0–195.9, 199.1–199.9). The registers do not contain informa-
tion on treatment, but specific diagnostic groups were expected to 
have received specific treatments. For example, patients who were 
treated for a hematological malignancy most likely received che-
motherapy.  A  subgroup  of  men  who  were  presumed  to  have 
received  radiotherapy  was  identified—standard  treatment  for 
seminomatous testicular cancer stage I during the study period was 
abdominal irradiation—and we identified 480 Swedish men who 
CONTEXT AND CAVEATS
Prior knowledge
Many cancer treatments could potentially damage the DNA in the 
sperm of male cancer survivors, creating concern that their off-
spring may be at increased risk for birth defects. Previous studies 
have not been large enough to determine if the mode of concep-
tion could have an effect on the potential risk of birth abnormalities 
in these offspring.
Study design
Danish and Swedish registers were used to perform a population-
based linkage study to investigate the risk of birth abnormalities in 
the offspring of 8670 male cancer survivors conceived naturally or 
by assisted reproductive technologies.
Contribution
The incidence of major congenital birth abnormalities was higher 
in the offspring of male cancer survivors compared with fathers 
with no history of cancer, although the mode of conception did not 
contribute to this increased risk.
Implications
Male cancer survivors have a slightly increased risk of producing 
offspring with major birth abnormalities regardless of the mode of 
conception.
Limitations
The effect of different treatments on the risk of birth abnormalities 
could not be analyzed because information about specific cancer 
treatments for each patient was not available from the registries. 
The potential selective diagnosis of malformations in the offspring 
of male cancer survivors because of underlying patient concern is 
unknown.
From the Editors
 
were  diagnosed  with  seminomatous  testicular  cancer,  of  whom 
80%–85% (27) can be assumed to have had stage I tumors and 
therefore to have been treated with radiotherapy.
Sperm from MCSs used for ARTs can either be banked pre-
treatment sperm or fresh posttreatment sperm. Information about 
the  sperm  source  was  not  available  in  the  registers,  but  it  was 
obtained directly from fertility clinics for 205 of the 249 Swedish 
children conceived using ARTs. Because data suggest that DNA 
damage  induced  by  oncological  treatment  is  only  transient 
(9,12,28–30), the naturally conceived children of MCSs were also 
categorized according to whether they were born 1–2 years after 
their father was diagnosed with cancer or more than 2 years after 
diagnosis.  ARTs  children  were  omitted  because  the  timing  of 
semen collection (cryopreserved or fresh) was not always known 
and is not related to when the child was conceived. The children 
of MCSs were further subdivided by the father’s age at diagnosis 
(<18 years of age [childhood cancer] vs ≥18 years of age).
Birth Outcomes
Perinatal outcome data included gestational length, birth weight, 
weight for gestational age, and the presence and type, if any, of 
congenital abnormalities. For analytic purposes, the following di-
chotomous outcomes were defined: preterm delivery (gestational 400   Articles | JNCI  Vol. 103, Issue 5  |  March 2, 2011
age at birth <37 completed weeks), very preterm delivery (gesta-
tional age at birth <32 completed weeks), low birth weight (birth 
weight <2500 g), very low birth weight (birth weight <1500 g), and 
small for gestational age (birth weight < 10th percentile for gesta-
tional week and sex). Congenital abnormalities were defined in 
multiple ways: 1) any congenital abnormality, which included any 
child with any malformation registered in Denmark or Sweden, no 
matter how minor; 2) major abnormalities, from which children 
with minor abnormalities (preauricular appendices, patent ductus 
arteriosus in children born preterm, single umbilical artery, minor 
skin  malformations  [mainly  nevi])  and  inconsistently  registered 
conditions  (undescended  testicles,  congenital  hip  subluxation) 
were excluded; and 3) specific groups of abnormalities.
Statistical Analyses
We evaluated the potential associations between paternal history of 
cancer, mode of conception, and the above-mentioned outcomes 
using log-linear binomial models, which yielded effect estimates as 
risk  ratios  (RRs)  with  95%  confidence  intervals  (CIs).  We  first 
assessed the effects of paternal history of cancer and mode of concep-
tion separately for Denmark and Sweden, adjusting for year of birth 
(1-year categories), maternal age at birth (5-year categories), mater-
nal parity (0, 1, 2+ children), and maternal smoking during early 
pregnancy  (self-reported  at  first  prenatal  checkup,  in  gestational 
week 10–12) (yes or no), all previously shown to affect birth out-
comes (26,31–33). For outcomes with similar country-specific risk 
ratios, we repeated the analyses on the combined data, with paternal 
history of cancer and mode of conception in the same model, and 
adjusted for country and the above-mentioned covariates.
We  conducted  additional  analyses  of  the  effect  of  various 
aspects of paternal history of cancer on the risk of major congenital 
abnormalities in the offspring. We examined the effects of timing 
of  paternal  cancer  (childhood  cancer  vs  cancer  in  adulthood), 
semen source (cryopreserved pretreatment semen vs posttreatment 
semen), time since paternal cancer diagnosis, and specific cancer 
diagnosis categories. In addition, we investigated whether mode of 
conception modified the effect of paternal history of cancer on the 
risk of major abnormalities by including an interaction term (pater-
nal history of cancer X mode of conception) in the multivariable 
model.  Because  similar  associations  were  observed  for  IVF  and 
ICSI, results for the two ARTs groups are presented together.
To examine whether including more than one child per father 
in the analyses biased our results, we conducted supplementary 
analyses restricted to one child per father. Because the results of 
these analyses did not differ appreciably from the results of our 
primary analyses (data not shown), we present the results from 
analyses including all singleton children born to each man.
All analyses were performed using SAS, version 9.1.3, software 
(SAS Institute, Inc, Cary, NC). P values were calculated using a 
two-sided Wald test; values less than .05 were considered to be 
statistically significant.
Results
Study Population
A total of 1 777 765 singletons were born in Denmark and Sweden 
between January 1, 1994, through December 31, 2004 (Denmark) 
and December 31, 2005 (Sweden). Of these, 1 743 169 were con-
ceived naturally and had no paternal history of cancer, 8162 were 
conceived naturally and had a paternal history of cancer, 25 926 
were conceived using ARTs and had no paternal history of cancer, 
and 508 were conceived using ARTs and had a paternal history of 
cancer. The distribution of selected parental characteristics and 
birth outcomes among these children is presented in Table 1.
Among the 8670 children with a paternal history of cancer, the 
mean paternal age at cancer diagnosis was 26.4 years (26.3 years 
among  children  conceived  naturally,  and  28.9  and  28.3  years 
among children conceived using IVF and ICSI, respectively). Most 
(98.8%) MCSs who had fathered study children had only been 
diagnosed with a single cancer (Table 2). Additional paternal char-
acteristics for children born to MCSs are presented in Table 2.
Birth Weight, Gestational Length, and Weight for 
Gestational Age
Paternal history of cancer was not associated with low birth weight 
(RR = 0.97, 95% CI = 0.86 to 1.09), very low birth weight (RR = 
0.86, 95% CI = 0.62 to 1.19), preterm delivery (RR = 0.94, 95% CI 
= 0.85 to 1.04), or very preterm delivery (RR = 0.85, 95% CI = 0.66 
to 1.09). Danish children with a paternal history of cancer had a 
decreased risk of being born small for gestational age compared 
with children whose fathers had never been diagnosed with cancer 
(RR = 0.89, 95% CI = 0.80 to 0.99). In contrast, a paternal history 
of cancer was not associated with weight for gestational age in 
Swedish children (RR = 0.99, 95% CI = 0.90 to 1.10, P = .90).
Compared with natural conception, conceptions via both IVF 
and ICSI were associated with increased risks of low birth weight 
(IVF, RR = 1.54, 95% CI = 1.44 to 1.63, P < .001; ICSI, RR = 1.53, 
95% CI = 1.41 to 1.67, P < .001), very low birth weight (IVF, 
RR = 1.88, 95% CI = 1.62 to 2.17, P < .001; ICSI, RR = 1.84, 95% 
CI = 1.51 to 2.23, P < .001), preterm birth (IVF, RR = 1.55, 95% 
CI = 1.47 to 1.64, P < .001; ICSI, RR = 1.39, 95% CI = 1.29 to 
1.49, P < .001), very preterm birth (IVF, RR = 1.86, 95% CI = 1.66 
to  2.08,  P  <  .001;  ICSI,  RR  =  1.75,  95%  CI  =  1.49  to  2.05, 
P < .001), and being born small for gestational age (IVF, RR = 1.03, 
95% CI = 0.99 to 1.08, P = .17; ICSI, RR = 1.10, 95% CI = 1.04 to 
1.16, P = .001).
Congenital Abnormalities
Children with a paternal history of cancer had an increased risk of 
any congenital abnormality (RR = 1.12, 95% CI = 1.02 to 1.24, P 
= .0183) and an increased risk of major abnormalities (RR = 1.17, 
95% CI = 1.05 to 1.31, P = .0043), compared with children without 
a paternal history of cancer, with 3.7 vs 3.2 incidents of major ab-
normalities per 100 offspring. When we examined paternal his-
tories of childhood and adulthood cancer separately (Table 3), the 
children of childhood cancer survivors had a greater risk of major 
abnormalities than the children of fathers diagnosed in adulthood, 
although the difference was not statistically significant (RR = 1.19, 
95%  CI  =  0.89  to  1.59,  P  =  .24).  When  we  stratified  on  time 
between  cancer  diagnosis  and  the  child’s  birth,  the  effect  of  a 
paternal history of cancer on the risk of major abnormalities was 
stronger among children born within 2 years of their father’s can-
cer diagnosis (RR = 1.27, 95% CI = 0.89 to 1.80) than among 
children born to fathers conceiving later (>2 years after diagnosis) jnci.oxfordjournals.org    JNCI | Articles 401
(RR = 1.16, 95% CI = 1.03 to 1.31), although the difference was 
not statistically significant. Children with paternal histories of skin 
cancers (RR = 1.36, 95% CI = 1.08 to 1.72, P = .008) and eye and 
central nervous system cancers (RR = 1.44, 95% CI = 1.08 to 1.91, 
P = .012) had statistically significant increased risks of major con-
genital abnormalities, whereas increases that fell short of statistical 
significance were seen in children with paternal histories of respi-
ratory, digestive, and urogenital tract cancers (excluding testicular 
cancer),  and  hematological  malignancies.  Among  children  with 
fathers belonging to these groups, a 19%–44% increased risk of 
major congenital abnormalities was seen compared with children 
without a paternal history of cancer (Table 3). In contrast, children 
with a paternal history of testicular cancer, as well as children born 
to Swedish fathers with a specific history of seminomatous testic-
ular cancer, were no more likely than children without a paternal 
history of cancer to have major abnormalities (Table 3; seminoma 
data not shown). When we examined specific classes of congenital 
abnormalities, a positive association with a paternal history of can-
cer was suggested for alimentary tract atresia, cleft lip, cystic kid-
ney, hypospadias, renal agenesis/reduction defects, limb reduction, 
phacomatosis, pyloric stenosis, and syndactyly (Table 4).
Children conceived using ARTs had a 20% increased risk of 
major congenital abnormalities compared with children conceived 
naturally (RR = 1.20, 95% CI = 1.12 to 1.28, P < .001). Mode of 
conception did not modify the association between paternal his-
tory of cancer and risk of congenital abnormalities (natural con-
ceptions, RR = 1.17, 95% CI = 1.04 to 1.31; ARTs, RR = 1.22, 
95% CI = 0.80 to 1.87; Pinteraction = .84). Of the children of Swedish 
MCSs conceived via ARTs (n = 249), 55% (n = 137) were con-
ceived using fresh posttreatment semen and 27% (n = 68) were 
Table 1. Parental characteristics and birth characteristics for singleton children born in Denmark (1994–2004) and Sweden (1994–2005), 
by paternal history of cancer and mode of conception (N = 1 777 765)*
Characteristic
No paternal history of cancer Paternal history of cancer
Natural IVF ICSI Natural IVF ICSI
Total No. of children,† (%) 1 743 169 (98.5) 16 536 (0.9) 9390 (0.5) 8162 (94.1) 205 (2.4) 303 (3.5)
Parental characteristics          
  Mean maternal age at birth, y 29.9 34.2 33.3 31.6 34.5 32.8
  Mean paternal age at birth, y 32.6 36.3 36.4 35.6 37.6 36.5
  Maternal smoking early in pregnancy, No. (%)          
    No 1 362 907 (78.2) 13 390 (81.0) 7962 (84.8) 6593 (80.8) 163 (79.5) 258 (85.2)
    Yes 280 480 (16.1) 2097 (12.7) 833 (8.9) 1089 (13.3) 22 (10.7) 24 (7.9)
    Missing 99 782 (5.7) 1049 (6.3) 595 (6.3) 480 (5.9) 20 (9.8) 21 (6.9)
  Maternal parity, No. (%)          
    Nulliparous 739 048 (42.4) 12 288 (74.3) 7157 (76.2) 3194 (39.3) 149 (72.7) 210 (69.3)
    Parous, 1 child 647 858 (37.2) 3445 (20.8) 1842 (19.6) 3202 (39.2) 47 (22.9) 82 (27.1)
    Parous, ≥2 children 356 262 (20.4) 803 (4.9) 391 (4.2) 1766 (21.6) 9 (4.4) 11 (3.6)
    Missing 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Birth characteristics          
  Sex, No. (%)          
    Male 895 333 (51.4) 8746 (52.9) 4610 (49.1) 4185 (51.3) 110 (53.7) 148 (48.8)
    Female 847 825 (48.6) 7790 (47.1) 4780 (50.9) 3977 (48.3) 95 (46.3) 155 (51.2)
    Missing 11 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Gestational age at birth, No. (%), wk          
    ≤32 15 237 (0.9) 348 (2.1) 169 (1.8) 61 (0.8) 5 (2.4) 6 (2.0)
    33–36 67 825 (3.9) 1093 (6.6) 540 (5.8) 302 (3.7) 14 (6.8) 23 (7.6)
    ≥37 1 653 984 (94.9) 15 080 (91.2) 8677 (92.4) 7773 (95.2) 186 (90.7) 274 (90.4)
    Missing 6123 (0.4) 15 (0.1) 4 (0.04) 26 (0.3) 0 (0.0) 0 (0.0)
  Birth weight, No. (%), g          
    <1500 9279 (0.5) 240 (1.5) 113 (1.2) 35 (0.4) 3 (1.5) 6 (2.0)
    1500–2499 46 294 (2.6) 811 (4.9) 427 (4.6) 219 (2.7) 10 (4.9) 13 (4.3)
    ≥2500 1 678 211 (96.3) 15 390 (93.1) 8803 (93.8) 7859 (96.3) 191 (93.2) 282 (93.1)
    Missing 9385 (0.5) 95 (0.6) 47 (0.5) 49 (0.6) 1 (0.5) 2 (0.7)
  Weight for gestational age, No. (%)          
    ≤10th percentile 171 226 (9.8) 2091 (12.7) 1202 (12.8) 742 (9.1) 21 (10.2) 32 (10.6)
    >10th percentile 1 558 502 (89.4) 14 341 (86.7) 8138 (86.7) 7350 (90.1) 183 (89.3) 269 (88.8)
    Missing 13 441 (0.8) 104 (0.6) 50 (0.5) 70 (0.9) 1 (0.5) 2 (0.7)
  Any congenital abnormality, No. (%)          
    No 1 666 732 (95.6) 15 646 (94.6) 8873 (94.5) 7772 (95.2) 188 (91.7) 290 (95.7)
    Yes 76 437 (4.4) 890 (5.4) 517 (5.5) 390 (4.8) 17 (8.3) 13 (4.3)
  Major congenital abnormality, No. (%)          
    No 1 687 074 (96.8) 15 930 (96.3) 9024 (96.1) 7863 (96.3) 192 (93.7) 293 (96.7)
    Yes 56 095 (3.2) 606 (3.7) 366 (3.9) 299 (3.7) 13 (6.3) 10 (3.3)
*  ICSI = intracytoplasmatic sperm injection; IVF = in vitro fertilization.
†  Percentages do not add up to 100% due to rounding error.402   Articles | JNCI  Vol. 103, Issue 5  |  March 2, 2011
conceived  using  cryopreserved  pretreatment  semen;  data  were 
missing for the remaining 18% (n = 44) of children. The preva-
lence  of  major  congenital  abnormalities  in  children  conceived 
using fresh posttreatment semen and those conceived using cryo-
preserved pretreatment semen was comparable (4.4% [six of 137] 
and 4.4% [three of 68], respectively).
A subanalysis restricted to Swedish children and therefore in-
cluding only cancer diagnoses registered in Sweden in the defini-
tion of paternal history of cancer did not appreciably alter our 
results (data not shown), which suggests that small differences in 
the registration of cancer patients in Denmark and Sweden did not 
affect our results.
Discussion
In this study, Danish and Swedish registries including 1 777 765 
singleton children born between 1994 and 2004 (Denmark) and 
2005 (Sweden) were used to investigate the relationship between 
paternal history of cancer and the mode of conception on perinatal 
outcomes in offspring. A paternal history of cancer was not associ-
ated with either low birth weight or preterm delivery. However, a 
paternal history of cancer was associated with a 17% increased risk 
of  major  congenital  malformations,  an  association  that  was  not 
modified by mode of conception. Apart from results from a recent 
study that found that first-born children of MCSs had an increased 
risk of congenital abnormalities (RR = 1.5, 95% CI = 1.1 to 2.3) 
Table 2. Paternal characteristics for 8670 singleton children born at or after 1 year after a paternal cancer diagnosis, by mode of 
conception*,†
Paternal characteristic
Mode of conception
Total (n = 8670) Natural (n = 8162) IVF (n = 205) ICSI (n = 303)
Mean age at cancer diagnosis, y 26.3 28.9 28.3 26.4
Cancer diagnosis,‡ No. (%)      
  Respiratory/digestive/urogenital tract§ 1114 (13.6) 20 (9.8) 14 (4.6) 1148 (13.2)
  Testicle 2259 (27.7) 68 (33.2) 161 (53.1) 2488 (28.7)
  Skin 1687 (20.7) 39 (19.0) 18 (5.9) 1744 (20.1)
  Eye and central nervous system 1054 (12.9) 13 (6.3) 10 (3.3) 1077 (12.4)
  Bone and soft tissue 430 (5.3) 3 (1.5) 8 (2.6) 441 (5.1)
  Blood and lymphatic system 1211 (14.8) 53 (25.9) 84 (27.7) 1348 (15.5)
  All other diagnoses 407 (5.0) 9 (4.4) 8 (2.6) 424 (4.9)
No. of diagnoses (%)      
  1 8065 (98.8) 204 (99.5) 293 (96.7) 8562 (98.8)
  >1 97 (1.2) 1 (0.5) 10 (3.3) 108 (1.2)
*  ICSI = Intracytoplasmatic sperm injection; IVF = in vitro fertilization.
†  Men who fathered more than one child post-cancer diagnosis are counted multiple times.
‡  See “Exposure” in “Materials and Methods” for the International Classification of Diseases-7 codes included in each category.
§  Testicular cancer was excluded.
Table 3. Prevalence and risk ratios for the association between paternal history of cancer and the risk of major congenital abnormal-
ities, by type of paternal cancer, paternal age at cancer diagnosis, and time between cancer diagnosis and birth*
Characteristic No. Prevalence, % Adjusted† RR (95% CI)
No paternal history of cancer (N = 1 769 095) 57 067 3.2 1.00 (referent)
Any paternal history of cancer (8670 total patients) 322 3.7 1.17 (1.05 to 1.31)
Paternal history of specific cancer types    
  Respiratory/digestive/urogenital tract‡ 45 3.9 1.26 (0.94 to 1.68)
  Testicle 76 3.1 0.98 (0.78 to 1.22)
  Skin 77 4.4 1.36 (1.08 to 1.72)
  Eye and central nervous system 47 4.4 1.44 (1.08 to 1.91)
  Bone and soft tissue 8 1.8 0.54 (0.26 to 1.12)
  Blood and lymphatic system 51 3.8 1.19 (0.90 to 1.57)
  All other diagnoses 18 4.3 1.30 (0.82 to 2.07)
Paternal age at cancer diagnosis, y    
  <18 (n = 1337) 56 4.2 1.36 (1.05 to 1.77)
  ≥18 (n = 7333) 266 3.6 1.14 (1.01 to 1.29)
Time between cancer diagnosis and birth, y§    
  ≤2 (n = 774) 31 4.0 1.27 (0.89 to 1.80)
  >2 (n = 7388) 268 3.6 1.16 (1.03 to 1.31)
*  CI = confidence interval; RR = risk ratio.
†  Adjustments were made for country (Denmark vs Sweden), year of birth (1-year categories), maternal age at birth (5-year categories), maternal parity (0, 1, ≥ 2), 
maternal smoking during early pregnancy (yes or no), and mode of conception (natural, IVF, or ICSI).
‡  Testicular cancer was excluded.
§  Only naturally conceived children were included.jnci.oxfordjournals.org    JNCI | Articles 403
(35),  our  findings  with  respect  to  congenital  abnormalities  are 
contrary  to  those  reported  in  previous  studies  (2,6,36–40). 
However, our study is the largest of its kind, to our knowledge, and 
was better powered to detect modest associations between paternal 
history  of  cancer  and  congenital  abnormalities  than  previous 
studies because of the relatively large number of patients.
Concern for the health of the offspring of MCSs is founded 
mostly  on  the  theoretical  adverse  effects  cancer  treatment  may 
have on sperm quality. In animal models, chemotherapy adminis-
tered in doses equivalent to those received by humans undergoing 
treatment for cancer has been shown to be mutagenic (41). In ad-
dition, both radio- and chemotherapy have been shown to induce 
DNA damage in human sperm, albeit only transiently, with both 
decreased  DNA  integrity  (8,9,11)  and  chromosomal  damage 
(10,28,42) observed. However, increased damage to sperm DNA 
has also been shown in cryopreserved pretreatment semen from 
cancer patients (8,12,13,43), suggesting that the cancer itself may 
also diminish sperm quality.
We were unable to directly examine the effect of paternal his-
tory of specific treatments for cancer on birth outcomes because 
neither national cancer register contains complete information on 
treatment (eg, the Danish Cancer Register only contains informa-
tion  on  treatment  completed  within  4  months  of  diagnosis). 
However, specific groups of cancers can generally be expected to 
be  treated  in  standard  ways.  Consequently,  in  subanalyses,  we 
examined the effect of paternal histories of specific groups of can-
cer diagnoses that were presumed to have received the same treat-
ment, as a proxy for the effect of a paternal history of specific 
cancer treatments. Although we recognize that use of such a coarse 
proxy measure was not ideal and our results must be interpreted 
with caution, our findings are suggestive nonetheless.
Whereas paternal history of hematological malignancy, gener-
ally treated with chemotherapy, was associated with a non-statisti-
cally  significant  increased  risk  of  congenital  abnormalities 
compared with children with no paternal history of cancer, no such 
increased risk was seen among children with a paternal history of 
testicular  seminoma,  the  majority  of  which  would  have  been 
treated with radiotherapy (stage I disease) (27). In contrast, a pater-
nal  history  of  skin  cancer,  for  which  the  standard  treatment  is 
surgical excision only, conferred an almost 40% increased risk of 
Table 4. Paternal history of cancer and risk of specific congenital abnormalities in children born in Denmark (1994–2004) and Sweden 
(1994–2005) (N = 1 777 765) (34)*
Type of congenital abnormality
Paternal history of cancer
RR (95% CI)† P‡
Yes (n = 8670) No (n = 1 769 095)
No. of patients Prevalence, % No. of patients Prevalence, %
Any 420 4.84 77 844 4.40 1.12 (1.02 to 1.24) .018
Any major 322 3.71 57 067 3.23 1.17 (1.05 to 1.31) .004
Selected groups of congenital abnormalities§          
Abdominal wall 3 0.03 511 0.03 1.2 (0.4 to 3.7) .76
Alimentary tract atresia 14 0.16 1704 0.10 1.7 (1.0 to 2.8) .054
Cardiovascular 88 1.01 17 772 1.00 1.0 (0.9 to 1.3) .92
Central nervous system 8 0.09 1915 0.11 0.9 (0.4 to 1.7) .65
Chromosomal, non-Down 2 0.02 1179 0.07 0.3 (0.1 to 1.4) .13
Cleft lip 17 0.20 2731 0.15 1.3 (0.8 to 2.0) .33
Cleft palate 8 0.09 1410 0.08 1.2 (0.6 to 2.3) .68
Club foot 15 0.17 2657 0.15 1.2 (0.7 to 1.9) .58
Craniosynostosis 5 0.06 967 0.05 1.1 (0.4 to 2.5) .90
Cystic kidney 7 0.08 547 0.03 2.6 (1.2 to 5.5) .012
Diaphragmatic hernia 1 0.01 447 0.03 0.5 (0.1 to 3.2) .43
Down syndrome 5 0.06 1941 0.11 0.5 (0.2 to 1.3) .15
Hypospadias 27 0.31 4506 0.25 1.2 (0.8 to 1.8) .30
Kidney dysgenesis, agenesis or hypoplasia 5 0.06 440 0.02 2.3 (1.0 to 5.6) .061
Limb reduction 10 0.12 912 0.05 2.2 (1.2 to 4.2) .011
Neural tube 5 0.06 777 0.04 1.3 (0.5 to 3.2) .54
Phacomatosis 4 0.05 336 0.02 2.4 (0.9 to 6.5) .078
Polydactyly 7 0.08 1659 0.09 0.8 (0.4 to 1.8) .69
Pyloric stenosis 13 0.15 1493 0.08 1.8 (1.0 to 3.1) .04
Skeletal 2 0.02 375 0.02 1.1 (0.3 to 4.4) .91
Syndactyly 11 0.13 1510 0.08 1.5 (0.8 to 2.7) .19
*  CI = confidence interval; RR = risk ratio.
†  The estimates for “any congenital abnormality” and “any major congenital abnormality” are adjusted for mode of conception, country, year of birth, maternal age 
at birth, maternal parity, and maternal first-trimester smoking; the class-specific estimates are unadjusted.
‡  P values were calculated using two-sided Wald test.
§  International Classification of Diseases (ICD-9) codes (Sweden)/ICD-10 codes (Denmark): abdominal wall, 756H/Q79.2–Q79.5; alimentary tract atresia, 750D or 
751C-D/Q39 or Q41–42; cardiovascular, 745–747, excluding 747A and 747F/Q20–Q28, excluding Q25.0 and Q27.0; central nervous system, 742B or 742D-X/
Q02-Q04 or Q06; chromosomal, non-Down, 758, excluding 758A/Q91–Q99; cleft lip, 749B-C/Q36–Q37; cleft palate, 749A/Q35; club foot, 754F/Q66.0; craniosyn-
ostosis, 756A/Q75.0–Q75.1; cystic kidney, 753B/Q62; diaphragmatic hernia, 756G/Q79.0–Q79.1; Down syndrome, 758A/Q90; hypospadias, 752G/Q54; kidney 
dysgenesis, agenesis or hypoplasia, 753A/Q61; limb reduction, 755C-E/Q71–Q73; neural tube, 740–742A/Q00-Q01 or Q05; phacomatosis, 759F-G/Q85; polydac-
tyly, 755A/Q69; skeletal, 756E-F/Q77–Q78; syndactyly, 755B/Q70.404   Articles | JNCI  Vol. 103, Issue 5  |  March 2, 2011
such abnormalities. The role of chance should always be consid-
ered when multiple subanalyses are performed, and no clear con-
clusions in relation to specific diagnoses should be drawn. However, 
these findings suggest that the increased risk of congenital abnor-
malities may be related more to paternal disease than to treatment 
for said disease. Although we cannot rule out that the observed 
increase  in  risk  of  congenital  abnormalities  among  children 
fathered by MCSs may be due to treatment-induced sperm DNA 
damage, this modest increase in risk could be due either to a direct 
effect of cancer itself on sperm DNA quality or to a constitutional 
genetic instability that contributed to the risks of both developing 
cancer early in life and conceiving a child with a birth defect. The 
latter possibility is supported by the fact that the rate of congenital 
abnormalities  among  ARTs  children  with  a  paternal  history  of 
cancer was similar using either pretreatment (“unexposed”) or post
treatment (“exposed”), although this information was only avail-
able for a small number of children.
Because ARTs can be used to conceive children in situations 
where the percentage of sperm with DNA strand breaks excludes 
the possibility of natural conception, a further increase in the risk 
of adverse birth outcomes could theoretically be anticipated when 
MCSs  use  IVF  or  ICSI  to  conceive  their  children.  However, 
although we found independent increases in the risk of major con-
genital abnormalities associated with both a paternal history of 
cancer  and  conception  using  ARTs,  the  risk  associated  with  a 
paternal history of cancer was not further increased in children 
conceived using either IVF or ICSI.
The study was based on Danish and Swedish national popula-
tion-based registers, all of which have previously been extensively 
validated and demonstrated to have excellent coverage (17–19,21–
25,36). The feasibility of combining national registers from the 
Nordic countries has previously been demonstrated (4).
Despite the strengths associated with the register-based nature 
of our study, register-based designs are also subject to certain lim-
itations, although we have attempted to minimize, or at least to 
delineate, their impact on our findings. Although the Scandinavian 
registers are known to have good coverage, the potential for mis-
classification due to incomplete case registration is always a con-
cern.  Registration  of  incident  cancer  patients,  however,  is 
considered to be close to complete in both Denmark and Sweden 
(22,25). Consequently, there is likely to have been little misclassi-
fication of a paternal history of cancer. Furthermore, subanalyses 
revealed that the small differences in the diagnoses registered in 
the two countries did not affect our results.
Similarly,  registration  of  birth  characteristics  such  as  birth 
weight and gestational age by the Danish and Swedish Medical 
Birth  Registers  is  also  considered  close  to  complete  (18,21). 
However,  registration  of  congenital  abnormalities  may  be  less 
complete, as many abnormalities are not immediately apparent at 
birth. Despite these potential limitations, we were able to extend 
follow-up for congenital abnormalities by up to 11 years through 
use of records from the Danish and Swedish Hospital Discharge 
Registers and the Swedish Register of Congenital Malformations.
Our results show that the risk of major abnormalities was stron-
ger  (although  not  statistically  significantly  so)  among  children 
born within 2 years of their father’s cancer diagnosis and that the 
strength of the association between a paternal history of cancer and 
the risk of congenital abnormalities was similar for many classes of 
abnormalities.  These  results  could  support  the  theory  that  the 
offspring of MCSs, particularly those of men treated shortly before 
conceiving their children, may be more vigilant in having congen-
ital  abnormalities  diagnosed  due  to  concerns  about  their  own 
health. However, a transient effect of treatment on sperm DNA 
quality  could  also  produce  the  pattern  seen  with  time  between 
paternal cancer diagnosis and birth.
Further questions about the birth outcomes of offspring from 
MCSs  still  need  to  be  addressed.  For  example,  are  offspring 
fathered by childhood cancer survivors at greater risk of congenital 
abnormalities  than  those  fathered  by  adult  cancer  survivors? 
Furthermore,  treatment  data  are  necessary  to  disentangle  the 
potential contributions of cancer itself and different treatments to 
the observed increased risk of congenital abnormalities among the 
offspring of MCSs supported by our study. However, our findings 
provide evidence that a paternal history of cancer may not be asso-
ciated  with  most  adverse  perinatal  outcomes.  Furthermore,  if 
confirmed in subsequent studies, the modest increase in risk of 
major congenital abnormalities associated with a paternal history 
of cancer may not be compounded by the use of ARTs.
Appendix 1: Data Sources
Denmark
Civil  Registration  System  (23):  Updated  daily  and  includes  all  residents  of 
Denmark, their civil status, links to their parents, and a unique personal identifi-
cation number, allowing linkage of information from population-based health 
registers.
Medical Birth Register (18): Established in 1973 and contains information on 
all live and stillbirths in Denmark.
IVF Register (17): Established in 1994 and records all treatments with IVF, 
ICSI, frozen embryo replacement, and egg donation, with coverage close to 100% 
(mandatory reporting nationwide).
Cancer Register (25): Records information on cancer patients in Denmark 
since 1943, including information on site of tumor (ICD-7 codes), histological 
type (ICD-O codes), with completeness shown to be 95%–98%.
Hospital Discharge Register (34): Contains discharge diagnoses (up to 
20) for all hospitalizations (from 1978) and outpatient visits (from 1996) in 
Denmark.
Sweden
Total Population Register: The civil registration of the inhabitants of Sweden, 
assigning all a unique personal identification number.
Multigenerational Register (24): Contains information on first-degree rela-
tives of all Swedish citizens born after 1931 and still alive in 1961, or born in 1961 
or later, with close to 100% coverage.
Medical  Birth  Register  (21):  Covers  nearly  all  (>98%)  children  born  in 
Sweden. Between 1993 and 2005, IVF and ICSI treatments were given at 18 
public or private clinics, with data on all treatments leading to delivery of a baby 
reported  to  the  Swedish  National  Board  of  Health,  and  thereby  to  the 
register.
Cancer Register (22): Mandatory reporting of cancers in Sweden since 1958, 
with agreement between clinical and cytological or histological diagnoses close to 
100% coverage. Information includes site of tumor (ICD-7 codes), histological 
type (ICD-O/2 codes for 1994-2004 and ICD-O/3 codes for 2005), and basis of 
and date of diagnosis.
Congenital  malformations:  Information  retrieved  from  the  Medical  Birth 
Register, and supplemented with data from the Swedish Register of Congenital 
Malformations (19), and the Hospital Discharge Register (44). Records from the 
various registries were compared, with the most detailed diagnoses for each child 
used (20).jnci.oxfordjournals.org    JNCI | Articles 405
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